

## Donal McLornan publications

### Publications

- (1) Gunawan AS, McLornan DP, Wilkins B, Waghorn K, Hoade Y, Cross NC, Harrison CN. Ruxolitinib, a potent JAK1/JAK2 inhibitor, induces temporary reductions in the allelic burden of concurrent CSF3R mutations in chronic neutrophilic leukemia. *Haematologica*. 2017 Mar [Epub ahead of print] PubMed PMID: 28302714.
- (2)\* Dowse R and McLornan DP. Principles of Haematopoietic Stem Cell Transplantation. *Medicine* - March 2017 in press
- (3) Saeed I, McLornan DP and Harrison CN. Managing side effects of JAK inhibitors for Myelofibrosis in Clinical Practice. *Expert Review in Hematology*. March 2017 in press
- (4) Sarma A, McLornan D and Harrison CN. Spotlight on Anagrelide Hydrochloride for the treatment of Essential Thrombocythaemia. *Orphan Drugs: Research and Reviews*: Jan 2017 Volume 2017:7 Pages 11—23
- (5) Butt NM, Lambert J, Ali S, Beer PA, Cross NC, Duncombe A, Ewing J, Harrison CN, Knapper S, McLornan D, Mead AJ, Radia D, Bain BJ; British Committee for Standards in Haematology.. Guideline for the investigation and management of eosinophilia. *Br J Haematol*. 2017; 176(4):553-572. PubMed PMID: 28112388.
- (6) Alkhatabi HA, McLornan DP, Kulasekararaj AG, Malik F, Seidl T, Darling D, Gaken J, Mufti GJ. RPL27A is a Target of miR-595 and may contribute to the Myelodysplastic Phenotype through Ribosomal Dysgenesis. *Oncotarget*. 2016 Jul 26;7(30):47875-47890. PMID: 27374104
- (7) Beauverd Y, Alimam S, McLornan DP, Radia DH, Harrison CN. Disease characteristics and outcomes in younger adults with primary and secondary myelofibrosis. *Br J Haematol*. 2016 Jun 13. [Epub ahead of print] PubMed PMID: 27293069.
- (8) Kordasti S, Costantini B, Seidl T, Perez Abellan P, Martinez Llordella M, McLornan D, Diggins KE, Kulasekararaj A, Benfatto C, Feng X, Smith A, Mian SA, Melchiotti R, de Rinaldis E, Ellis R, Petrov N, Povoleri GA, Sook Chung S, Thomas NS, Farzaneh F, Irish JM, Heck S, Young NS, Marsh JC, Mufti GJ. Deep-phenotyping of Tregs identifies an immune signature for idiopathic aplastic anemia and predicts response to treatment. *Blood*. 2016 Jun 8. [Epub ahead of print] PubMed PMID: 27281795.
- (9) O'Sullivan JM, McLornan DP, Harrison CN. Safety considerations when treating myelofibrosis. *Expert Opin Drug Saf*. 2016 Jun 1:1-8. [Epub ahead of print] PubMed PMID: 27187785

- (10) Curto-García N, Harrison CN, McLornan DP, Radia DH. Thiamine deficiency appears uncommon in patients with Myeloproliferative Neoplasms. *Br J Haematol*. 2016 May [Epub ahead of print] PubMed PMID: 27135305.
- (11) Tobiasson M, McLornan DP, Karimi M, Dimitriou M, Jansson M, Azenkoud AB, Jädersten M, Lindberg G, Abdulkadir H, Kulasekararaj A, Ungerstedt J, Lennartsson A, Ekwall K, Mufti GJ, Hellström-Lindberg E. Mutations in histone modulators are associated with prolonged survival during azacitidine therapy. *Oncotarget*. 2016 Mar [Epub ahead of print] PubMed PMID:26959885.
- (12) Dowse R, Ibrahim M, McLornan DP, Moonim MT, Harrison CN, Radia DH. Beneficial effects of JAK inhibitor therapy in Systemic Mastocytosis. *Br J Haematol*. 2016 Feb [Epub ahead of print] PubMed PMID: 26847591.
- (13)\* Tedjaseputra A, Galli S, Ibrahim M, Harrison CN, McLornan DP. Histone Deacetylase Inhibitors in Myeloproliferative Neoplasms: Current Roles and Future Prospects. *Expert Opinion on Orphan Drugs*. 2016 Feb [Epub ahead of print] DOI:10.1517/21678707.2016.1149467
- (14) Beauverd Y, McLornan DP, Radia DH, Harrison CN. Ruxolitinib: evolution or revolution in treatment of patients with polycythemia vera? *Future Oncol*. 2016 Feb [Epub ahead of print] PubMed PMID: 26846873.
- (15) Shanavas M, Popat U, Michaelis LC, Fauble V, McLornan D, Klisovic R, Mascarenhas J, Tamari R, Arcasoy MO, Davies J, Gergis U, Ukaegbu OC, Kamble RT, Storrington JM, Majhail NS, Romee R, Verstovsek S, Pagliuca A, Vasu S, Ernst B, Atenafu EG, Hanif A, Champlin R, Hari P, Gupta V. Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors. *Biol Blood Marrow Transplant*. 2015 Oct. [Epub ahead of print] PubMed PMID: 26493563.
- (16) Beauverd Y, McLornan DP, Harrison CN. Pacritinib: a new agent for the management of myelofibrosis? *Expert Opin Pharmacother*. 2015 Oct; (15):2381-90. PubMed PMID: 26389774.
- (17) Alimam S, McLornan D, Harrison C. The use of JAK inhibitors for low-risk myelofibrosis. *Expert Rev Hematol*. 2015 Oct; 8(5):551-3. PubMed PMID: 26343888.
- (18) Harrison CN, McLornan DP, Francis YA, Woodley C, Provis L, Radia DH. How We Treat Myeloproliferative Neoplasms. *Clin Lymphoma Myeloma Leuk*. 2015 Jun;15 Suppl:S19-26. PubMed PMID: 26297273.
- (19) Kröger NM, Deeg JH, Olavarria E, Niederwieser D, Bacigalupo A, Barbui T, Rambaldi A, Mesa R, Tefferi A, Griesshammer M, Gupta V, Harrison C, Alchalby H, Vannucchi AM, Cervantes F, Robin M, Ditschkowski M, Fauble V, McLornan D, Ballen K, Popat UR, Passamonti F, Rondelli D, Barosi G. Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group. *Leukemia*. 2015 Nov;29(11):2126-33. Review. PubMed PMID: 26293647.
- (20)\* McLornan DP, Khan AA, Harrison CN. Immunological Consequences of JAK Inhibition: Friend or Foe? *Curr Hematol Malig Rep*. 2015 Aug 21. [Epub ahead of print] PubMed PMID: 26292803.

- (21) Keohane C, McLornan DP, Sanchez K, Connor C, Radia D, Harrison CN. The effects of JAK inhibitor therapy upon novel markers of thrombosis in myeloproliferative neoplasms. *Haematologica*. 2015 Jun [Epub ahead of print]
- (22)\* Keohane C, Kordasti S, Seidl T, Perez Abellan P, Thomas NS, Harrison CN, McLornan DP, Mufti GJ. JAK inhibition induces silencing of T Helper cytokine secretion and a profound reduction in T regulatory cells. *Br J Haematol*. 2015 Jun [Epub ahead of print] PubMed PMID: 26075866. [Joint senior Author]
- (23)\* Khan AA, Harrison CN, McLornan DP. Targeting of the Hedgehog pathway in myeloid malignancies: still a worthy chase? *Br J Haematol*. 2015 May. [Epub ahead of print] PubMed PMID: 25892100.
- (24)\* McLornan DP, List A, Mufti GJ. Applying synthetic lethality for the selective targeting of cancer. *N Engl J Med*. 2014 Oct 30;371(18):1725-35. PubMed PMID: 25354106.
- (25) Wang M, Wang W, Abeywardane A, Adikarama M, McLornan D, Raj K, de Lavallade H, Devereux S, Mufti GJ, Pagliuca A, Potter VT, Mijovic A. Autoimmune Hemolytic Anemia after Allogeneic Hematopoietic Stem Cell Transplantation: Analysis of Adult Patients Who Underwent Transplantation at King's College Hospital. *Biol Blood Marrow Transplant*. 2014 Sep. [Epub ahead of print]. PubMed PMID: 25262883.
- (26)\* Mwirigi A, Galli S, Keohane C, Raj K, Radia DH, Harrison CN, McLornan DP. Combination therapy with ruxolitinib plus 5-azacytidine or continuous infusion of low dose cytarabine is feasible in patients with blast-phase myeloproliferative neoplasms. *Br J Haematol*. 2014 Jul. [Epub ahead of print] PubMed PMID: 25048366.
- (27) Clay J, Kulasekararaj AG, Potter V, Grimaldi F, McLornan D, Raj K, de Lavallade H, Kenyon M, Pagliuca A, Mufti GJ, Marsh JC. Nonmyeloablative Peripheral Blood Haploidentical Stem Cell Transplantation for Refractory Severe Aplastic Anemia. *Biol Blood Marrow Transplant*. 2014 Jul. PMID: 25016195
- (28) Galli S, McLornan D, Harrison C. Safety evaluation of ruxolitinib for treating myelofibrosis. *Expert Opin Drug Saf*. 2014 Jul; 13(7):967-76. PMID: 24896661.
- (29) Raj K, Pagliuca A, Bradstock K, Noriega V, Potter V, Streetly M, McLornan D, Kazmi M, Marsh J, Kwan J, Huang G, Getzendaner L, Lee S, Guthrie KA, Mufti GJ, O'Donnell P. Peripheral blood hematopoietic stem cells for transplantation of hematological diseases from related, haploidentical donors after reduced-intensity conditioning. *Biol Blood Marrow Transplant*. 2014 Jun; 20(6):890-5. PMID: 24650678.
- (30)\* Harrison C, McLornan D. Myelofibrosis. *Hematology*. 2014 Mar; 19(2):120-1. PMID: 24611775.
- (31)\* McLornan DP, Harrison C. Combination therapies in Myeloproliferative Neoplasms: why do we need them and how to identify potential winners? *J Cell Mol Med*. 2013 Nov; 17(11):1410-4

- (32) Jovanovic JV, Ivey A, Vannucchi AM, Lippert E, Oppliger Leibundgut E, Cassinat B, Pallisgaard N, Maroc N, Hermouet S, Nickless G, Guglielmelli P, van der Reijden BA, Jansen JH, Alpermann T, Schnittger S, Bench A, Tobal K, Wilkins B, Cuthill K, McLornan D, Yeoman K, Akiki S, Bryon J, Jeffries S, Jones A, Percy MJ, Schwemmers S, Gruender A, Kelley TW, Reading S, Pancrazzi A, McMullin MF, Pahl HL, Cross NC, Harrison CN, Prchal JT, Chomienne C, Kiladjian JJ, Barbui T, Grimwade D. Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study. *Leukemia*. 2013 Oct; 27(10):2032-9.
- (33)\* McLornan DP, Hay J, McLaughlin K, Holohan C, Burnett AK, Hills RK, Johnston PG, Mills KI, McMullin MF, Longley DB. Prognostic and therapeutic relevance of c-FLIP in Acute Myeloid Leukaemia. *Br J Haematol*. 2013 ;160(2):188-98.
- (34)\* McLornan DP. Principles of Haematopoietic Stem Cell Transplantation. *Medicine* - May 2013; Vol. 41, Issue 5: 302-305
- (35)\* McLornan D, Laurie J, Harrison CN. Review of Treatment Options for Myelofibrosis: Focus on Ruxolitinib. *Clinical Medicine Insights: Therapeutics* 2013 Jan; 5: 15-24. doi 10.4137
- (36)\* McLornan DP, Mead A, Jackson G, Harrison CN. State of the Art Review: Allogeneic Stem Cell Transplantation for Myelofibrosis in 2012. *Br J Haematol*. 2012 May;157(4):413-25. doi: 10.1111
- (37) Yapa HM, McLornan DP, Raj K, Streetly M, Kazmi M, Cuthill K, Laurie J, Menon PA, Macmahon E. Pneumonitis post-haematopoietic stem cell transplant - cytopathology clinches diagnosis. *J Clin Virol*. 2012 Nov;55(3):278-81.
- (38)\* McLornan DP, Barrett HL, Cummins R et al (2010). Prognostic significance of TRAIL signaling molecules in Stage II and III colorectal cancer. *Clin Cancer Res*. 2010 Jul 1;16(13):3442-51. PMID: 20570920
- (39)\* McLornan DP, Burthem J, Duncombe A et al (2010). British Society of Haematology, Slide Session presented at the Annual Scientific Meeting, Brighton 2009. *Int J Lab Hematol*. 2010 Dec;32(6 Pt 2):616-24. PMID: 20491999
- (40)\* McLornan DP and McMullin MF (2008). How would I manage a case of essential thrombocythaemia presenting with an ischaemic toe? *Hematological Oncology* 26(1): 3-7. PMID: 17968846
- (41)\* McLornan DP, McMullin MF, Johnston PG et al (2007). Molecular mechanisms of drug resistance in acute myeloid leukaemia. *Expert Opinion in Drug Metabolism and Toxicology*,3(3):363-77. PMID: 17539744
- (42)\* McLornan DP, McMullin MF (2006). JAK2 V617F: a single mutation amongst the myeloproliferative group of disorders. *Ulster Medical Journal* 75(2): 112-9. PMID: 16755940

(43)\* McLornan DP, Percy MJ, Jones AV et al (2005). Chronic neutrophilic leukaemia with an associated V617F JAK2 tyrosine kinase mutation. *Haematologica* 90(12):1696-7. PMID: 16330446

(44) Ghandimathi K, McLornan DP, O'Neill F (2004). Hepatic capsule Haemorrhage due to HELLP syndrome managed with recombinant VIIa. *Clinical Intensive Care*.15 (1):15-18

## Book Chapters

\* Donor Lymphocyte Infusions. McLornan DP, Potter VT and Dazzi F.  
Submitted for publication in *Current Concepts and Controversies in Hematopoietic Cell Transplantation*.